CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,296 enrolled
Drug / intervention
Patients with Benign Prostate Hyperplasiaother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04831476
NCT04831476N/ACompleted

A Non Interventional Post Authorisation Multicenter Study to Evaluate the Disease Control (Benign Prostate Hyperplasia Control) and Quality of Life (QoL) Following the 6-months Combination Treatment With Dutasteride and Tamsulosin. PROSPERITY Group of Studies (I&II).

Elpen Pharmaceutical Co. Inc.·observational·Posted Apr 5, 2021·Updated Oct 18, 2023

In Brief

An observational study evaluating Patients with Benign Prostate Hyperplasia for Benign Prostatic Hyperplasia. Completed, enrolled 1,296 participants across 1 site.

Detailed Summary

Investigation of the efficacy and safety of the stable combination of dutasteride and tamsulosin (Dinaplex®) in the Greek population as well as the evaluation of the quality of life of patients with benign prostatic hyperplasia (BPH) in treatment with a stable combination of dutasteride and tamsulosin (Dinaplex®)

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesGreece
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedApr 5, 2021
Enrollment StartSep 1, 2021
Primary CompletionOct 31, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.2 years ago

Interventions

Patients with Benign Prostate Hyperplasiaother

patients with benign prostatic hyperplasia under fixed dose combΙnation treatment with dutasteride and tamsulosin